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Abstract 
 
Intermediate filaments (IFs) are one of the three major filaments of the cytoskeleton. Due to their 
intrinsic physical properties, IFs provide mechanical support and give cells the elastic properties that 
allow them to resist deformation and maintain their shape. Different from actin filaments and microtu-
bules, IFs have a cell type-specific expression pattern, and in mature astrocytes, the main IF protein 
expressed is the glial fibrillary acidic protein (GFAP). Although the exact function of GFAP remains 
unclear, GFAP is overexpressed in response to a variety of insults to the Central Nervous System (CNS) 
and the deletion of GFAP renders mice more susceptible to neurotoxicity. Furthermore, heterozygous 
gain-of-function mutations in the GFAP gene cause Alexander disease (AxD), a progressive and fatal 
neurodegenerative disorder that most frequently affects newborns and infants. IFs are the least charac-
terized filaments of the three major cytoskeleton elements. Difficulties in studying the behavior of these 
filaments, and in particular of GFAP, arise from the fact that these proteins do not tolerate well the 
presence of protein tags in its termini. Therefore, we aimed to create new and more versatile molecular 
tools to study the behavior of GFAP in living cells, and that can easily be implemented in the study of 
other IFs. In this work, we developed a mouse GFAP-HaloTag fused system and the first tagged version 
of human GFAP. Both versions of tagged GFAP were able to incorporate into the IF network and form 
a normal filamentous network when transiently transfected in mammalian U251 cells. Opposingly, 
R236H/R239C AxD-causing mutations disrupted the endogenous filament network of GFAP and altered 
its diffusion properties. Furthermore, our results also show that GFAP dynamics is intimately linked to 
that of actin microfilaments and microtubules, as cytoskeleton-destabilizing drugs completely change 
the diffusion properties of GFAP molecules. Taken together, the results in this thesis demonstrate the 
enormous potential our two novel systems have for the study of GFAP oligomerization, aggregation, 
and dynamics in living cells.  
 
 
 
Keywords: Astrocytes, Intermediate filaments, GFAP, Alexander disease, HaloTag 
  
  
iv 
Resumo 
 
A habilidade de uma célula de resistir a deformação, transportar carga intracelular ou de mudar a 
sua forma durante o movimento depende do citoesqueleto. O citoesqueleto é uma rede complexa de 
filamentos proteicos e proteínas motoras associadas que se estende pelo citoplasma de todas as células, 
incluindo bactérias e arquea. Em células eucarióticas, o citoesqueleto é composto por três tipos de polí-
meros, distinguíveis entre si pelo tamanho: filamentos de actina ou microfilamentos (7 nm de diâmetro), 
microtúbulos (24 nm) e filamentos intermédios (10 nm). Contrariamente aos microfilamentos e microtú-
bulos, cuja composição é muito semelhante entre todos os tipos celulares, a composição dos filamentos 
intermédios varia consideravelmente entre diferentes tipos de células, tecidos e órgãos, durante o desen-
volvimento e em condições patológicas. Os filamentos intermédios são estruturas extremamente estáveis 
que fornecem suporte e protegem as células de danos mecânicos ao conferir-lhes propriedades elásticas 
para resistir à deformação e manter a sua forma. Além destas funções de suporte, estes filamentos de-
sempenham ainda um papel na sobrevivência, divisão e migração celular. Devido à multitude de funções 
nas quais os filamentos intermédios participam, alterações nos níveis de expressão ou mutações em 
componentes específicos destes filamentos estão associadas ao aparecimento de várias patologias, a sua 
grande maioria raras. Apesar da sua enorme estabilidade, os filamentos intermédios são estruturas bas-
tante dinâmicas e muitas vezes a participação dos microtúbulos e dos filamentos de actina é fundamental 
para a manutenção da sua rede.  
 
A proteína ácida fibrilar glial (GFAP) é o filamento intermédio mais característico dos astrócitos, 
e é universalmente utilizada como o principal marcador para a sua identificação e classificação. Apesar 
da estrutura tridimensional desta proteína permanecer desconhecida, pensa-se que possua uma estrutura 
tripartida que é semelhante entre todos os filamentos intermédios. Esta estrutura consiste num domínio 
central alfa-helicoidal altamente conservado flanqueado por dois domínios N-terminal e C-terminal, sem 
uma estrutura secundária definida. Assim como os restantes filamentos intermédios, a GFAP tende a 
formar filamentos com 10 nm de diâmetro. Primeiramente, ocorre a formação de um dímero através da 
interação entre os domínios centrais de dois monómeros, que se enrolam um sobre o outro para formar 
uma estrutura superenrolada. De seguida, estes dímeros associam-se de forma antiparalela para formar 
tetrâmeros apolares. Posteriormente, com a contribuição dos domínios N-terminais, os tetrâmeros asso-
ciam-se para formar protofilamentos que, por sua vez, se associam lateralmente para formar os filamen-
tos maturos, com vários nanómetros de comprimento. Contrariamente aos restantes filamentos do cito-
esqueleto, a construção dos filamentos intermédios é totalmente independente de nucleótidos. Para além 
de fornecer suporte mecânico aos astrócitos, pensa-se que a GFAP tenha também um papel importante 
na migração e motilidade celular, na mitose e ainda na manutenção da barreira hematoencefálica. A 
GFAP está também associada a várias patologias do sistema nervoso central, tais como a doença de 
Alexander. A doença de Alexander é uma doença neurodegenerativa rara, fatal e progressiva que afeta 
essencialmente recém-nascidos e crianças. Esta doença resulta do aparecimento de mutações pontuais 
no gene que codifica para a GFAP e é caracterizada pela acumulação massiva deste filamento intermé-
dio, juntamente com proteínas de stress, em estruturas citoplasmáticas complexas, denominadas por 
fibras de Rosenthal.  
 
Atualmente, os filamentos intermédios são os polímeros menos caracterizados do citoesqueleto e o 
nosso conhecimento atual relativamente à sua estrutura tridimensional, bem como dos processos dinâ-
micos envolvidos na sua construção, está muito longe de estar completo. Esta escassez de conhecimento 
relativamente à organização e dinâmica dos filamentos intermédios deve-se em parte à dificuldade em 
visualizar estes filamentos in vivo. Isto acontece porque estes filamentos, e em particular a GFAP, não 
toleram bem a presença de marcadores proteicos nos seus terminais, como por exemplo as proteínas 
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fluorescentes, já que estes causam a rutura ou desorganização dos filamentos e levam à sua agregação. 
Assim, o principal objetivo deste trabalho é desenvolver novos modelos celulares para o estudo da oli-
gomerização, função e dinâmica da GFAP em células vivas. 
 
No presente estudo, começámos por construir um plasmídeo no qual a GFAP de ratinho foi ligada 
a uma HaloTag (mGFAP-HT), de forma a puder estudar a arquitetura e o comportamento da GFAP a 
um nível nanoscópico. A HaloTag é uma alternativa atrativa às proteínas fluorescentes, uma vez que 
combina a especificidade genética destas proteínas com as propriedades foto-físicas superiores de ligan-
dos orgânicos, uma característica que a torna muito apelativa para microscopia de super-resolução e 
outras técnicas avançadas. Neste trabalho desenvolvemos também com sucesso a primeira versão mar-
cada da GFAP de humano inserindo, de forma aleatória, a proteína fluorescente EGFP dentro da região 
codificante da GFAP. Quando expressos transientemente nas células de glioblastoma humano U251, 
ambos os sistemas foram capazes de se integrar na rede de filamentos intermédios endógena destas 
células e de formar estruturas filamentosas típicas da GFAP em aproximadamente 90% das células. 
 
Por forma a estudar o efeito que as mutações relacionadas com a doença de Alexander têm na 
construção dos filamentos da GFAP, gerámos o mutante de ratinho R236H e o mutante de humano 
R239C, por mutagénese dirigida. Os nossos resultados mostram que na maioria das células transfetadas 
com os plasmídeos mutantes, a GFAP não é capaz de formar uma rede filamentosa. No entanto, o com-
portamento da GFAP mutante não é o mesmo nos dois modelos. Enquanto que o mutante de humano 
R239C formou maioritariamente pequenos agregados, o mutante de ratinho R236H formou um padrão 
homogéneo disperso pelo citoplasma das células, sem nenhuma estrutura filamentosa aparente. Embora 
vários esforços continuem a ser feitos para tentar encontrar um composto que seja eficaz contra a doença 
de Alexander, a verdade é que esta doença permanece intratável e incurável. No entanto, estudos recen-
tes demonstraram que a especiaria curcumina tem um efeito benéfico na redução da agregação da GFAP. 
Desta forma, decidimos testar o efeito neuroprotetor de dois compostos sintéticos e derivados da curcu-
mina, J147 e CNB-001, na redução da agregação do mutante humano R239C. Observámos que, no nosso 
modelo celular, o composto CNB-001 é mais eficaz que o J147 e que apenas as células que cresceram 
na presença de CNB-001(10 µM) mostraram um aumento ligeiro, embora significativo, na formação de 
filamentos e uma respetiva diminuição da agregação da GFAP. 
 
O plasmídeo mGFAP-HT foi ainda utilizado para estudar a dinâmica da GFAP de ratinho. Os nos-
sos resultados mostram que a mutação R236H tem um forte efeito na dinâmica da GFAP, aumentando 
consideravelmente a sua velocidade de difusão, comparativamente à GFAP não mutada. Os filamentos 
intermédios estão em constante comunicação com os restantes elementos do citoesqueleto, e muitas 
vezes a sua dinâmica está dependente destes. Os nossos resultados são consistentes com estas observa-
ções, e demonstram que a despolimerização dos microfilamentos de actina ou dos microtúbulos resulta 
numa diminuição significativa da velocidade de difusão das moléculas de GFAP, e num aumento da 
percentagem de moléculas com uma difusão mais lenta. 
 
Em suma, os resultados apresentados neste trabalho demonstram o enorme potencial dos dois sis-
temas que construímos no estudo da função, oligomerização e dinâmica da GFAP em células vivas. Em 
teoria, estas estratégias, podem também ser utilizadas para o estudo de qualquer outro filamento inter-
médio. O desenvolvimento de novos e mais versáteis modelos celulares, continua, no entanto, a ser 
indispensáveis para uma melhor compreensão do comportamento da GFAP em células vivas e também 
dos mecanismos pelos quais mutações nesta proteína causam a doença de Alexander.  
 
Palavras-chave: Astrócitos, Filamentos intermédios, GFAP, Doença de Alexander, HaloTag 
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1. Introduction 
 
 
1.1. Intermediate Filaments: a key component of the cytoskeleton 
 
The structural framework of a cell is provided by the cytoskeleton, a complex network of protein-
aceous filaments and motor proteins that extends throughout the cytoplasm of all cells, including bacte-
ria and archaea1. The cytoskeleton is an adaptive and dynamic structure that helps cells divide, move, 
maintain their shape and regulate the traffic of intracellular cargo through the cytoplasm, among other 
important functions2. Three major types of polymers, distinguishable by their size, make up the cyto-
skeleton of eukaryotic cells: actin filaments or microfilaments, microtubules, and a group of polymers 
collectively known as intermediate filaments (IFs). Microtubules are formed by a few isoforms of tubu-
lin and are the thickest filaments with a typical diameter of 24 nm. These filaments are constantly as-
sembling and disassembling and play a crucial role in cell division and migration, and in the transport 
of intracellular cargo. Microfilaments are mainly formed by actin isoforms and reach 7 nm in diameter. 
They are involved in a variety of processes that require force, including muscle contraction and cell 
exploration and movement. Lastly, intermediate filaments, as the name suggests, have a diameter that 
falls between that of actin microfilaments and microtubules. These 10 nm-diameter filaments provide 
support for microfilaments and microtubules and give cells elastic properties that allow them to with-
stand tension1-4.  
 
In contrast to actin filaments and microtubules, the composition of the proteins making up interme-
diate filaments varies considerably between different tissues, organs, and cell types, during development 
or in pathological conditions5. Intermediate filaments are classified into five major types based on sim-
ilarities in amino acid sequence, protein structure predictions, and assembly properties6. Because IFs 
play such an important role in providing mechanical support to cells, changes in expression levels or 
mutations of specific IF components are associated with a multitude of tissue-specific degenerative dis-
orders7,8 (Table 1.1). 
 
Table 1.1: Classification of Intermediate filaments and associated pathologies.   
Class Proteins Localization Examples of diseases 
I and II Acidic and neutral-basic keratins Epithelial cells 
Epidermolysis bullosa simplex; epider-
molytic hyperkeratosis; monilethrix; 
keratodermas; 
III 
Vimentin Mesenchymal cells Dominant cataracts 
GFAP Astrocytes Alexander disease 
Desmin Muscle Desmin-related myopathy 
Peripherin Peripheral neurons Amyotrophic lateral sclerosis 1 
Syncoilin Muscle Desminopathy; muscular dystrophy 
IV 
Neurofilaments Central Nervous System Various Charcot-Marie-Tooth diseases; Parkinson disease 
a-Internexin Central Nervous System Amyotrophic lateral sclerosis; dementia 
Nestin Glial and neural precursor cells - 
Synemin Muscle Various cancers 
V Lamins (A, B1, B2, C) Cell nucleus Hutchinson-Gilford progeria syndrome; Acquired partial lipodystrophy 
Orphans 
(VI) 
Bfsp1 (filensin) 
Bfsp2 (phakinin) Lens cells 
Autosomal-dominant cataract 
Autosomal-recessive cataract 
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All IFs share a common tripartite structure consisting of a highly conserved a-helical central do-
main (rod domain) flanked by an amino (N)-terminal head domain and a carboxy (C)-terminal tail do-
main (Figure 1.1). The rod domain is divided into four hydrophobic a-helical segments of conserved 
length: 1A, 1B, 2A and 2B. These four segments are interconnected by three short linkers (L1, L12, and 
L2). The beginning and end parts of the rod domain are particularly conserved in all IFs. Both of these 
conserved regions are involved in dimer-dimer interactions and mutations in these regions are deleteri-
ous to IF organization and dynamics. On the contrary, the head and tail domains have very little second-
ary structure and their length and sequence vary considerably among different IF proteins.9-11 The three-
dimensional structures of most IFs, including GFAP, remain incompletely described and this is a major 
barrier to our understanding of their assembly, protein-protein interactions, and other functional proper-
ties.  
Intermediate filaments are very stable structures and until recently they were thought to have very 
limited dynamics when compared to actin filaments and microtubules. This assumption originated from 
the observation that most IFs in a cell were not extracted and remained intact after cell lysis with deter-
gents and high concentrations of salts12. However, recent studies demonstrated that IFs are highly dy-
namic structures that can shorten, elongate and rearrange in response to a wide variety of extracellular 
or intracellular stimuli13. IF dynamics often requires the participation of microtubules and actin fila-
ments. This contribution is particularly important in astrocytes, where microtubule- and actin-dependent 
transport are essential for the maintenance of the IF network14. 
 
Besides providing mechanical support to cells, IFs can also interact with cellular organelles either 
by forming cage-like structures around the nucleus, physically controlling their shape, position, and 
movement15,16; or by serving as anchoring structures for mitochondria, positioning them near high-en-
ergy-demanding sites17. Furthermore, a large body of evidence points to a key role for IFs in cell sur-
vival18, division19,20 and migration21,22. 
 
 
1.2. Glial Fibrillary Acidic Protein (GFAP) is a major intermediate filament typical of astrocytes 
 
Astrocytes are the most numerous cells in the human brain, outnumbering neurons by over fivefold. 
These specialized glial cells that display an enormous heterogeneity in their morphology and function 
were originally thought to have only a passive role in the central nervous system (CNS) in the mainte-
nance of neurons. However, over the past few decades, it has become clear that glial cells, particularly 
astrocytes, are involved in a wider variety of functions, vital for brain development, physiology and 
pathology23. The most characteristic IF protein expressed in astrocytes is the glial fibrillary acidic pro-
tein (GFAP), being universally used as a molecular marker for their identification and classification. 
This protein was initially discovered and isolated from patients with multiple sclerosis24 and its amino 
acid composition was presented for the first time in 196925. GFAP, together with vimentin and nestin, 
Figure 1.1: Schematic representation of IF protein structure. All IFs share a common tripartite structure with a conserved 
central rod domain flanked by a N-terminal head domain and a C-terminal tail domain. 
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makes up the intermediate filament system of astrocytes26. As astrocytes mature, typically GFAP ex-
pression increases, the nestin expression stops and vimentin expression decreases27,28. However, not all 
populations of astrocytes express GFAP and different combinations of IF expression profiles are possi-
ble29. 
 
The human GFAP gene is located on chromosome 17q21 and has nine exons and eight introns 
distributed over 10 kb in the human genome30. There are at least nine GFAP isoforms resulting from 
alternative mRNA splicing31,32 (Figure 1.2). In humans, GFAP-a is the predominant isoform in the 
CNS. It has 432 amino acids and a molecular weight of 50 kDa. GFAP-b is highly expressed in non-
myelinating Schwann cells in the peripheral nervous system (PNS) and has an alternative upstream 
transcriptional start site in the 5’ UTR. The GFAP-d isoform is the second most studied isoform and is 
differentially expressed in neurogenic astrocytes in the subventricular zone and the olfactory bulb. This 
isoform has 431 amino acids and is generated by alternative mRNA splicing combined with alternative 
polyadenylation of the intron 7, which generates a new exon E7a. Due to differences in the tail region, 
this isoform is no longer capable of assembling homomeric GFAP-d filaments but can form heteromeric 
intermediate filaments with GFAP-a or vimentin. Other isoforms include the GFAP-g isoform which 
lacks exon 1 and includes the last 126 nucleotides of intron 1-2; the splice variants 
GFAPDEx6, GFAPD164 and GFAPD135 that skip sequences in exon 6; the GFAP-k isoform that lacks 
exons 8 and 9 like GFAP-d but the exon 7a is replaced by exon 7b, with the entire intron 7; and the 
GFAP-z isoform, a transcript that includes the last 284 nucleotides of intron 8. The amino acid sequence 
of human GFAP-a has a very high similarity (91% identity and 95% positivity) to that of mouse GFAP 
(430 amino acids)33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.2: Different GFAP isoforms. At least nine GFAP transcript isoforms resulting from alternative mRNA splicing can 
be found in the central and peripheral nervous systems. Adapted from [32]. 
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Although the three-dimensional structure is unknown, it is believed that GFAP shares with other 
intermediate filaments a common structure with three major domains: a head domain with 72 amino 
acids (1-72 Aa), a central helical rod domain with 305 amino acids (73-377 Aa) and a (C)-terminal tail 
domain with 55 amino acids (378-432 Aa)34. Like other intermediate filament proteins, GFAP forms 10 
nm diameter filaments. The first stage of filament assembly is the formation of a dimer through the 
interaction of the rod domain of two polypeptide chains that wind around each other in a coiled-coil 
structure. These dimers then associate in an anti-parallel manner to form apolar tetramers, which are the 
initial building blocks of all IFs. With the contribution of the nonhelical tail domains, these tetramers 
then associate to form protofilaments, and eight protofilaments wind around each other to form unit-
length filaments (ULFs) that are 20 nm in diameter. Finally, the ULFs associate longitudinally to form 
filaments with hundreds of nanometers in length11,35. The extended filaments undergo radial compaction 
that reduces the diameter to 10 nm (Figure 1.3)36. Unlike microfilaments and microtubules, the assem-
bly of GFAP is totally nucleotide-independent 35. 
 
 
IFs are often subject to multiple post-translational modifications and GFAP is no exception. Phos-
phorylation, for example, plays a major role in the regulation of filament assembly/disassembly and in 
the structural organization of GFAP and other IFs37-39. Site-specific phosphorylation of GFAP by protein 
kinase A, calmodulin-dependent protein kinase II or protein kinase C is responsible for the disassembly 
of the filaments. The majority of phosphorylation sites are located in the head domain. Of the six phos-
phorylation sites identified, five (Thr-7, Ser-8, Ser-13, Ser-17, and Ser-34) occur in the head domain; 
the remaining one, Ser-389, is located in the tail domain38,39. Most of the amino acids that are subject to 
phosphorylation in the head domain of GFAP are conserved among species and GFAP isoforms, which 
reinforces the physiological importance of phosphorylation in the regulation of GFAP fibrillization31. 
GFAP can also be citrullinated in its arginine residues, which creates epitopes that evoke autoimmune 
responses40. Importantly, studies on post-translational modification were carried out in cell-free, in vitro 
systems using protein extracts or in fixed cells. This limitation was due, in part, to the lack of chimeric 
versions of GFAP that allowed their visualization in living cells until very recently14. IFs including 
GFAP, rarely tolerate protein tags directly fused to their N- or C-termini, and this constitutes a major 
hurdle in our understanding of the physio- and pathological functions of this protein. 
 
Similar to other IFs, GFAP is thought to provide mechanical support to astrocytes and help these 
cells to maintain their mechanical strength as well as their shape. However, the exact functions of GFAP 
remain elusive. Various studies using GFAP knockout or transgenic mice have provided some insights 
Figure 1.3: Representative scheme of IFs assembly. In the first stage of filament assembly, two GFAP molecules interact to 
form dimers. Two dimers associate in an anti-parallel manner to form apolar tetramers. Mature IFs are formed by the longitu-
dinal association of unit length filaments (ULFs), that result from the association of apolar tetramers. Adapted from [35]. 
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into the contribution of this protein in astrocyte physiology and pathology. GFAP plays very diverse 
roles in cell migration and motility41, in mitosis by regulating filament assembly required for cytokine-
sis42,43 or in vesicle trafficking, including the movement of vesicles for exocytosis, vesicle recycling, 
and lysosome-mediated autophagy44,45. Furthermore, GFAP is also suggested to be involved in the mod-
ulation of synaptic plasticity, by regulating the trafficking and the membrane anchoring of glutamate 
transporters46,47, in the maintenance of the blood-brain barrier and normal CNS myelination48. 
 
Studies using GFAP-null (GFAP-/-) mice have demonstrated that, despite all the cellular processes 
that this protein has been implicated in, GFAP is not essential in mice. GFAP-null mice displayed nor-
mal development, growth, fertility, and lifespan. When compared to wild-type mice, unchallenged 
GFAP-null mice showed no differences in brain architecture, and the blood-brain barrier was also in-
tact49-51. However, mice deficient for GFAP, displayed an increased fragility of the CNS when subjected 
to head injury, which suggests that GFAP plays an important role in neural protection. Some reports 
suggest that the apparently innocuous phenotype displayed by GFAP-/- mice is due to a redundancy in 
the function of intermediate filaments, as other intermediate filaments like vimentin or nestin could be 
compensating for the absence of GFAP53.  
 
In response to CNS injury and disease, astrocytes undergo a complex process called astrogliosis 
that is characterized by an increase in the number of astrocytes, profound morphological and neuro-
chemical changes in astrocytes, and an increase in the expression of GFAP54,55. The cellular and molec-
ular mechanisms that lead to astrogliosis are not completely understood, but neuroinflammatory path-
ways like the Janus Kinase/Signal Transducer and Activator of Transcription 3 (JAK/STAT3) signaling 
pathway appear to trigger astrogliosis. The activation of astrocytes can be induced by several cytokines 
such as ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) or interleukine-6 (IL-6), 
produced and secreted by damaged cells and microglia in the CNS56,57. Mutations or overexpression of 
GFAP over a toxic threshold can cause a lethal neurodegenerative disease known as Alexander disease58.  
 
 
1.3. Alexander Disease is caused by point mutations in GFAP 
 
Alexander Disease (AxD), described by Stewart Alexander in 1949, is a rare, fatal and progressive 
neurodegenerative disorder that most frequently affects newborns and infants. The first report of AxD 
described the case of an infant who died at 16 months of age after a several-month history of severe 
developmental delays, regressions in cognitive and motor skills, seizures and progressive macroceph-
aly59. According to the only population-based survey ever conducted, this disease has a prevalence of 1 
in 2.7 million60, although Messing et al.58 believe this number is an underestimate because symptoms 
are common to other disorders and often difficult to identify without previous clinical experience with 
this disorder. The disease occurs in both sexes, and there seems to be no predilection for race or ethnic-
ity58,61. 
 
The most common classification divides patients into three subtypes based on the age of onset: 
infantile (0-2 years), juvenile (2-12 years) and adult (>12 years)62. More recently, different classifica-
tions that rely on the distribution of lesions and clinical presentations rather than age of onset have been 
proposed. One of these alternative systems divides patients into two categories, type I and type II, with 
all type I cases being early-onset, and type II cases occurring at all ages63. Early-onset patients normally 
display a very different set of symptoms than late-onset patients. Early-onset patients have a prominent 
frontal-lobe involvement and typical symptoms include cognitive and motor developmental delays, 
megalencephaly, seizures, and hyperreflexia or spasticity. Patients with later onsets more often exhibit 
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hindbrain dysfunction and typically experience pseudobulbar symptoms such as ataxia, dysarthria and 
dysphonia, sleep disturbances and very rarely have megalencephaly or seizures58,61-63. Lifespan is related 
to age of onset with type I patients having a mean survival of 14 years and type II patients of 25 
years58,61,63. 
 
The genetic basis for AxD was defined in 2001 when Brenner and colleagues64 reported the pres-
ence of de novo mutations in 4 different GFAP residues in 10 unrelated AxD patients. At the moment, 
GFAP is the sole known cause of AxD, with approximately 95% of patients harboring mutations in the 
GFAP gene65. In the majority of cases, GFAP mutations are not inherited but arise spontaneously. All 
mutations detected so far are heterozygous and about 90% of these involve single amino acid changes, 
though insertions and deletions have also been reported66. Disease-causing mutations are only known to 
occur in the rod and tail domains of GFAP, with most of these mutations residing in the 1A, 2A and 2B 
segments of the conserved central rod domain of GFAP (Figure 1.4). Two mutation hotspots affecting 
amino acids R79 and R239 (equivalent to mouse GFAP R76 and R236, respectively) account for ~ 20% 
of all reported cases of AxD. These two missense mutations produce the greatest variety of substitutions 
and cause a particular severe disease61,63-67. 
 
AxD is genetically dominant and mutations appear to act in a gain-of-function manner, as GFAP-
null mice display a phenotype that does not resemble AxD49-51. However, it is still unclear if this mech-
anism is due to a gain of a normal function or gain of an abnormal function of GFAP. Analysis of various 
cases of AxD show that there is considerable phenotypic variability between affected individuals as (1) 
individuals with the same mutation display differences in severity of disease, (2) some patients with 
disease-causing mutations do not display symptoms, and (3) in rare cases of pathologically proven AxD, 
no mutation in GFAP has been found. The reasons for this variability are still unknown but some suggest 
that genetic modifiers and environmental factors may influence the appearance of disease symptoms61,68.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Distribution of Alexander disease-related mutations in GFAP in relation to protein domain structure of IFs 
and clinical presentation. Aminoacids R76 and R239 are two mutation hotspots that account for approximately 20% of all 
the AxD cases. These two missense mutations produce the greatest variety of substitutions and cause a particular severe disease. 
Adapted from [61]. 
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An increase in GFAP levels beyond a toxic threshold, triggered by the presence of mutant GFAP, 
leads to the formation of eosinophilic protein inclusions known as Rosenthal fibers (RFs) (Figure 1.5A). 
These cytoplasmic inclusions mainly contain GFAP and vimentin intermediate filaments in association 
with stress-related proteins like alpha-b-crystallin69 and the small heat shock protein hsp2770, as well as 
other proteins in varying amounts71. The sequestration of both alpha-b-crystallin and hsp27 in GFAP 
aggregates will most likely diminish the ability of astrocytes to cope with stress72,73 and prevent apop-
tosis74. RFs can be formed throughout the astrocyte and are thought to be generated by the continuous 
incorporation of small aggregates into larger inclusions, a process that continues to happen over time in 
parallel with the accumulation of GFAP (Figure 1.5B)75. Although RFs are characteristic of AxD, they 
can sometimes be found in other pathological contexts like glial scars76 or pilocytic astrocytomas77. 
However, their numbers and distribution in AxD are noticeably higher than in these other patholo-
gies68,78. Overexpression of wild-type GFAP can also lead to the formation of RFs that are indistinguish-
able from the ones found in AxD patients79. Both these results indicate that GFAP mutations, although 
not required for RF formation, may accelerate the process78.  
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Rosenthal fibers (RFs) are the major histopathological feature of Alexander disease (AxD). (A) Morpholog-
ical features of RFs. (B) Schematic representation of RF formation and growth. Adapted from [75]. 
 
 
Astrocytes in AxD display profound changes in cell shape and function, as AxD-causing mutations 
disturb the in vitro filament assembly and network formation of GFAP. When R239C GFAP was tran-
siently expressed into Vimentin-negative SW13 cells, the protein did not form a filamentous network 
but instead formed small aggregates throughout the cytoplasm of cells. Although the R239C mutant also 
formed aggregates in primary rat astrocytes, in some of the cells it was also able to incorporate into the 
endogenous GFAP networks. These data suggest that GFAP mutations do not necessarily prevent GFAP 
assembly but could affect the ability of ULFs to anneal and subsequently compact into filaments80,81. 
Some authors propose that the effect of the mutations is to slow down the rate of normal polymer for-
mation rather than to abolish it completely. To overcome the reduction in polymerization, astrocytes 
react in a self-destructive manner and increase the synthesis of mutant GFAP, resulting in a positive 
feedback loop for disease progression67. 
 
The accumulation of either wild-type or R239C GFAP in astrocytes impaired proteasome activity, 
but mutant GFAP produces a much stronger inhibitory effect. This proteasomal inhibition not only ag-
gravates GFAP accumulation and aggregation, which in turn causes further proteasome inhibition but 
may also prevent other proteins from being degraded81-83. GFAP aggregation also activates a number of 
stress pathways such as the MAPK, p38 and JNK pathways. Constitutive activation of JNK in astrocytes 
leads to an increase in GFAP levels by further inhibiting proteasome activity. On the other hand, p38 
activation produces the opposite effect as it negatively regulates mTOR activity, which in turn promotes 
A) 
 
A) 
B) 
 
B) 
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autophagy in an attempt to decrease GFAP levels84,85. Proteasome inhibition, and the consequent accu-
mulation of the short-lived transcription factor Nrf2, also triggers an oxidative stress response in astro-
cytes marked by activation of several oxidative stress-response genes86,87. Furthermore, aggregates of 
GFAP can alter the morphology and cellular localization of some membranous organelles, like ER and 
Golgi, segregating these organelles to a perinuclear position. Such morphological changes may disrupt 
vesicle formation and consequently intracellular and membrane trafficking75,88. 
 
Since astrocytes play so many important roles, alterations in astrocyte function can impact other 
cells of the CNS. Actually, AxD astrocytes do not die, but patients show a massive white matter loss 
indicative of neuronal loss. One of the most characteristic changes in AxD astrocytes is the decrease of 
its major glutamate transporter GLT-189. The loss of this transporter affects the ability of astrocytes to 
uptake and buffer glutamate released from synapses into the extracellular medium, which in turn can 
lead to neuronal hyperexcitability and death. Recent studies using both mouse and human models of 
AxD show that AxD astrocytes induce a strong inflammatory environment characterized by an upregu-
lation of inflammatory genes regulated by NF-kB-mediated gene transcription, a marked activation of 
microglia and a modest influx of T cells into the CNS90. 
 
At the moment, treatments for AxD can only address symptoms, but several strategies for therapy 
have been proposed91. One approach is to screen libraries of drugs or compounds to reduce the accumu-
lation of GFAP, either by regulating the activity of the GFAP promotor or by increasing its degrada-
tion92. For example, the IL-6 family of cytokines induces GFAP expression by means of the JAK/STAT3 
and/or MAPK pathways. Specific targeting of these or other cytokines or rate-limiting events in these 
pathways could be achieved by means of drugs, gene therapy or immunotherapy (with intrabodies, for 
example). Another possible approach is to minimize downstream effects of GFAP toxicity, such as the 
deficit in the expression of the glutamate transporter GLT-193-95. Enhancing protective stress responses 
such as those involving Nrf296,97 or alpha-b-crystallin98 could also be a promising target. 
 
 
 
 
 
2. Aims of the project 
 
 
Despite the knowledge we already have on GFAP, the spatio-temporal dynamics of this protein as 
well as the mechanisms by which GFAP mutations lead to astrocyte dysfunction remain poorly under-
stood. This is due, at least in part, to the difficulties in visualizing this intermediate filament in vivo. 
These difficulties arise from the fact that GFAP does not tolerate well the presence of fluorescent tags 
in its N- or C- termini since they are deleterious for filament assembly and lead to aggregation of the 
protein. 
 
With this in mind, the overall aim of this thesis is to develop new molecular tools to study GFAP 
location, oligomerization and dynamics in living cells without compromising its assembly and function. 
Our specific objectives are: 
 
1) Creating a new, more versatile tool for the study of mouse GFAP behavior by super-resolution 
microscopy or other advanced methods; and 
 
2) Developing the first tagged version of human GFAP for the study of its behavior in normal and 
AxD-related conditions. 
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3. Material and Methods 
 
3.1. Reagents 
 
Cloning enzymes were purchased from Thermo Scientific (Waltham, MA, USA) unless otherwise 
indicated. Exceptions include SrfI (New England Biolabs, Ipswich, MA, USA), PfuTurbo DNA poly-
merase (Agilent, Santa Clara, CA, USA) and DpnI and alkaline phosphatase (NZYTech, Lisbon, Portu-
gal). Cell culture media (Dulbecco’s Modified Eagle Medium - DMEM - and Leibovitz’s L-15 medium), 
Fetal Bovine Serum (FBS), penicillin-streptomycin commercial antibiotic mixture (Pen-Strep), L-glu-
tamine, TrypLE Express dissociation reagent, Ca2+- and Mg2+-free phosphate buffer saline (PBS) 1X 
and Leukemia inhibitory factor (LIF) were obtained from Gibcoâ (Waltham, MA, USA). PCR primer 
synthesis and DNA sequencing were performed by StabVida (Caparica, Portugal). Janelia Fluor 646 nm 
(JF646) and Janelia Fluor 549 nm (JF549) HaloTag ligands were obtained from Promega Corporation 
(Madison, WI, USA) and the photoactivatable Janelia Fluor 549 nm (PA-JF549) HaloTag ligand was a 
kind gift from Dr. Luke Lavis (HHMI’s Janelia research campus, Ashburn, VA, USA). Nocodazole was 
acquired from TargetMol (Wellesley Hills, MA, USA) and Latrunculin B from Focus Biomolecules 
(Plymouth Meeting, PA, USA). J147 and CNB-001 drugs were a kind gift from Dr. David Schubert 
(The Salk Institute for Biological Studies, LA Jolla, CA, United States). The following antibodies were 
used: rabbit anti-GFAP (1:1000, Sigma-Aldrich, St. Louis MO, USA), mouse anti-GADPH (1:2000, 
Santa Cruz Biotechnologies, Inc., Dallas, TX, USA), goat anti-rabbit IgG-Horseradish Peroxidase 
(HRP) conjugate (1:10000, Invitrogen, Carlsbad, CA, USA) and goat anti-mouse IgG-HRP conjugate 
(1:10000, Bio-Rad Laboratories, Hercules, CA, USA). Chemiluminescent HRP substrate was purchased 
from Bio-Rad Laboratories (Hercules, CA, USA). Human glioblastoma U251 cells were obtained from 
Public Health England (Salisbury, UK). The pEGFP-N3-mGFAP plasmid was a kind gift from Dr. 
Cécile Leduc (Institut Pasteur, Paris, France), the pZH504 Halo-Cro plasmid was kindly gifted by Dr. 
Zach Hensel (ITQB, Oeiras, Portugal) and the pcDNA3.1-EGFP-hGFAP plasmid encoding the human 
GFAP was developed at our laboratory by Ricardo Letra-Vilela.   
 
3.2. Plasmid construction and site-directed mutagenesis 
 
All plasmids were constructed using the conventional restriction digestion and ligation cloning 
technique. Vector and insert DNA fragments were obtained by restriction digestion of a host plasmid 
and through PCR amplification using Phusion polymerase, respectively. 
 
3.2.1. Construction of a mouse GFAP-HaloTag fused plasmid 
For the mGFAP-HaloTag construct, the host vector was obtained by substitution of the EGFP tag 
from a pEGFP-N3-mGFAP plasmid for a HaloTag using BamHI and NotI restriction sites (Figure 
3.1A). We initially used the restriction enzymes BamHI and XbaI, but the double digestion failed. When 
we separately single-digested the host plasmid with each restriction enzyme, BamHI was able to cleave 
its recognition site and produce a linear plasmid, but when we tried to digest with XbaI the digestion 
was not successful due to the methylation sensitivity of XbaI (Data not shown). To overcome this diffi-
culty, we opted to change the pair of restriction enzymes to BamHI and NotI. Firstly, we single- and 
double-digested the host plasmid with BamHI and NotI and both enzymes were able to cleave the plas-
mid and produce two bands, one which at 720 bp, the expected size for EGFP (Figure 3.1B). The Hal-
oTag was obtained by PCR-amplification of the pZH504 Halo-Cro plasmid using specific primers (Ta-
ble 3.1) and carrying BamHI and NotI restriction sites (Figure 3.1C lanes 2 and 3). PCRs were done 
using 20 ng of template DNA, 0.2 µM of cloning primers and 200 µM of dNTPs in a total volume of 50 
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µl containing 1 unit of Phusion DNA polymerase and the corresponding amplification buffer. The ther-
mocycling conditions were the following: denaturation at 98ºC for 30 s followed by 30 cycles of 98ºC, 
10 s; 65ºC, 30 s; 72ºC, 30 s (30 s/kb, as specified by the manufacturer) and a final extension at 72ºC for 
10 min. Insert and vector fragments were digested for 2 h at 37ºC. Digested vectors were further incu-
bated with 0.5 units of alkaline phosphatase for 1 h at 37ºC to prevent spontaneous religation of the 
vector. Digested vectors were then isolated by agarose gel electrophoresis (1% in Tris-acetate-EDTA – 
TAE - 1X) and purified with a NZYGelpure kit (NZYTech, Lisbon, Portugal). Digested vectors and 
inserts were ligated for 2 h at room temperature using 5 units T4 DNA ligase. Four different molar ratios 
of vector: insert were used – 1:0, 1:3, 1:6 and 1:9 – with the 1:0 ratio serving as a control for non-specific 
vector religation. Ligation products were transformed into NZY5a competent E. coli bacteria 
(NZYTech, Lisbon, Portugal) by heat shock and grown overnight at 37ºC on LB Agar 1X Petri dishes 
containing 50 µg/ml of kanamycin or 100 µg/ml of ampicillin for selection of transformed clones. Two 
different methods were used to determine if the cloning was successful. First, plasmids from randomly 
chosen colonies were isolated, digested with restriction enzymes and the resulting products analyzed by 
agarose gel electrophoresis. As shown in Figure 3.1D, in all of the tested colonies, plasmid digestion 
with BamHI and NotI generated 2 bands, one corresponding to the linearized plasmid and another in 
accordance with the size of the HaloTag (891 bp). To further confirm the cloning efficacy, 3 positive 
clones were sequenced, and in all the presence of the HaloTag was confirmed. No insertions or deletions 
were observed but all the clones had a single nucleotide mutation, that did not change the amino acid 
sequence. This mutation was probably present in the original template for HaloTag PCR amplification. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Cloning strategy for the construction of a mouse GFAP-HaloTag (mGFAP-HT) fused plasmid. (A) The 
HaloTag protein was amplified as a 5’BamHI-3’NotI PCR fragment and cloned into a BamHI-NotI digested pEGFP-N3-GFAP 
plasmid. (B) Test digestion of the pEGFP-N3-GFAP plasmid; M – marker; lane 1- undigested plasmid; lane 2 - Single-digestion 
with BamHI; lane 3 – Single-digestion with NotI; lane 4 – Double-digestion with BamHI and NotI. (C) Vector and insert DNA 
fragments used for the construction of the mGFAP-HT plasmid. Vector fragments were prepared by double-digestion of the 
pEGFP-N3-GFAP plasmid with BamHI and NotI (lane 1) and insert fragments were obtained by PCR-amplification of a 
pZH504 Halo-Cro plasmid (lanes 2 and 3). (D) Confirmation of correct plasmid assembly by digestion with BamHI and NotI 
restriction enzymes. Positive clones are indicated by an arrow. 
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3.2.2. Construction of tagged human GFAP constructs 
All cloning procedures were done as described in the previous subsection. Human GFAP constructs 
were obtained by substitution of the EGFP tag in our in-house pcDNA3.1-EGFP-hGFAP plasmid by 
Venus 1 (amino acids 1-157), Venus 2 (amino acids 158-238) or full-length HaloTag inserts. For these 
operations, we used the restriction enzymes AscI and SrfI. The Venus 1, Venus 2 and HaloTag inserts 
were amplified as 5’AscI – 3’SrfI PCR fragments using a pCS2-Venus or the pZH504 Halo-Cro plas-
mids as templates and the primers described in Table 3.1.  
 
3.2.2. Site-directed mutagenesis 
Single p. Arg236His (R236H) and p. Arg239Cys (R239C) mutations were individually inserted by 
site-directed mutagenesis into the wild-type mGFAP and hGFAP constructs, respectively. PCRs were 
carried out using 25 ng of template DNA, 0.2 µM of mutagenesis primers (Table 3.1.) and 250 µM of 
dNTPs in a total volume of 50 µl containing 2.5 units of Pfu turbo DNA polymerase and the correspond-
ing amplification buffer. The following thermocycling conditions were used: denaturation at 95ºC fol-
lowed by 12 cycles of 95ºC, 30 s; 55ºC, 1 min; 68ºC, 8 min (1 min/kb, as specified by the manufacturer) 
and a final extension at 68ºC for 5 min. Mutagenesis reactions were then incubated with DpnI for 1 h at 
37ºC to digest methylated parental plasmids and later transformed by heat shock into NZY5a competent 
bacteria. Transformed bacteria were grown overnight at 37ºC on LB Agar 1X Petri dishes with 50 µg/ml 
of kanamycin or 100 µg/ml of ampicillin for selection. Plasmids from randomly chosen colonies were 
isolated using a ZYMO Research Miniprep kit and sequenced to confirm the presence of the mutations. 
 
 
Table 3.1: Sequences of primers (5' ® 3') used to construct plasmids encoding tagged GFAP or in site-directed muta-
genesis of these constructs 
 
 
Construct Primer sequence (5’ ® 3’) 
mGFAP - HaloTag 
Forward: AATGGATCCATGGCAGAATCGGTACTGGC 
Reverse: TATGCGGCCGCTTAGCCGGAAATCTCGAG 
hGFAP - Venus 1 
Forward: AATGGCGCGCCATGGTGAGCAAGGGCG 
Reverse: AATGCCCGGGCTTGCTTGTCGGCGGTGAT 
hGFAP – Venus 2 
Forward: AATGGCGCGCCAAGAACGGCATCAAGGC 
Reverse: AATGCCCGGGCGTACAGCTCGTCCATGC 
hGFAP - HaloTag Forward: AATGGCGCGCCATGGCAGAAATCGGTAC Reverse: ATAGCCCGGGCGCCGGAAATCTCGAGC 
Arg236His (R236H) Forward: CTGAGAGAGATTCACACTCAATACGAG Reverse: CTCGTATTGAGTGTGAATCTCTCTCAG 
Arg239Cys (R239C) Forward: CTGAAAGAGATCTGCACGCAGTATG Reverse: CATACTGCGTGCAGATCTCTTTCAG 
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3.3. Cell culture 
 
3.3.1. Cell growth, seeding and transfection 
Human glioblastoma U251 cells and rat glioma C6 cells were grown to confluence in 100 mm 
dishes (Thermo Scientific, Waltham, MA, USA) in DMEM, supplemented with 10% (v/v) fetal bovine 
serum (FBS), 1% (v/v) Penicillin-Streptomycin and 1% (v/v) L-glutamine and maintained at 37ºC in a 
humidified atmosphere containing 5% CO2. Medium was changed every other day and cells were passed 
once a week by trypsinization. Briefly, cells were incubated with TrypLE Express dissociation reagent 
for 5 min at 37ºC for cell detachment, followed by a centrifugation step at 300 g for 5 min at room 
temperature and sub-cultured according to the desired dilution. For fluorescent microscopy and single-
molecule tracking experiments, 3×105 cells were grown on 35 mm glass-bottom µ- dishes (21 mm glass 
surface diameter, ibidi GmbH, Gräfelfing, Germany). For flow cytometry, 3×105 cells were seeded on 
6-well plates (35 mm diameter, CorningÒ, Corning, NY, USA). For Western blotting, 8×105 cells were 
seeded on 60 mm dishes (Orange Scientific, Braine-L’Alleud, Belgium). Twenty-four hours after seed-
ing, cells were transiently transfected with 1 µg of the corresponding DNA constructs using jetPRIMEÒ 
transfection reagent (Polyplus transfection, Illkirch, France) in a proportion of 3:1 (µL of transfection 
reagent: µg of DNA).  
 
3.3.2. Drug treatments and cell labeling 
All drugs and HaloTag ligands were diluted in DMSO (100% v/v). To test the neuroprotective 
activity of J147 and CNB-001, cells were treated with 100 nM, 1 µM or 10 µM of each drug 20 min 
before transfection and incubated for 24 h at 37ºC. For single-molecule experiments, 24 h after trans-
fection, serum was removed for 2 h, and cells were treated with LIF (100 ng/ml), Nocodazole (10 µM) 
or Latrunculin B (10 µM) for 2 h at 37ºC in serum-free medium. Cells were then incubated with JF646 
(100 nM), JF549 (100 nM) or PA-JF549 (1 nM) HaloTag ligands in serum-free medium for 20 min at 
37ºC. Subsequently, cells were washed twice with sterile PBS. At the end of the final wash, the medium 
was changed to Leibovitz’s L-15 without phenol red. 
 
3.4. Microscopy 
 
Live-cell images of U251 cells were acquired at Instituto Gulbenkian de Ciência on a commercial 
widefield Nikon High Content Screening microscope, equipped with a 100x/1.45 plan-apo oil-immer-
sion objective and an Andor Zyla 4.2 Scientific complementary metal-oxide-semiconductor (sCMOS) 
camera. To image eGFP/Venus–fused proteins, a 470 nm laser line, and GFP fluorescence filter sets 
were used and for the imaging of HaloTag-fused proteins, a 635 nm laser line and Cy5 fluorescent filter 
sets were used. An exposure time of 80 ms was used and the camera readout bandwidth was set to 200 
MHz. The resulting pixel size was 65 nm using a 1024 x 1024 pixel as field of view. All acquisitions 
were done at room temperature. The microscope, cameras, and hardware were controlled through Nikon 
Elements software. Images were analyzed by means of the ImageJ free software. 
 
Single-molecule imaging and Super-Resolution Radial Fluctuations (SRRF) imaging were per-
formed on a Leica DMI6000 inverted microscope using a 100x/1.46 a-plan apochromat oil immersion 
objective. A 561 nm excitation laser (Coherent Sapphire) was set to 50 mW resulting in an effective 
power density of ~ 2.3 kW/cm2. The laser beam was passed through a custom filter cube (Chroma Tech-
nology) with a zet405/561x excitation filter, a zt405/561/657rpc-uf2 dichroic beamsplitter, and an 
et610/75m emission filter. Fluorescent light was imaged on an Evolve 512 electron-multiplying charge-
coupled device (EM-CCD) camera (Photometrics) after additional 1.6x magnification. An EM gain of 
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300 was used and the camera readout bandwidth was set to 10 MHz. The resulting pixel size was 100 
nm using a 512 x 512 pixel as field of view. The incubation chamber was maintained at 37°C. The 
microscope, cameras, and hardware were controlled through MetaMorph software (Molecular Devices). 
For single-molecule experiments and for each cell, 1000 frames were acquired at 33 ms exposure time 
with no interval between frames. No photoactivation was necessary as spontaneous photoactivation of 
PA-JF549 combined with photobleaching by 561 nm illumination gave a reasonable density of single 
molecules. The Trackmate ImageJ plugin99 was used to detect, fit and track individual GFAP molecules 
in living cells. For the detection of GFAP molecules, we selected a LoG detector and an estimated blob 
diameter of 0.4 µm and a threshold of 1500. For the tracking, we used a simple LAP tracker with a 
linking max. distance of 0.5 µm, a gap-closing max. distance of 0.5 µm and a gap-closing max. frame 
gap of 0. The average diffusion of GFAP molecules and its fractions, per individual cell, were calculated 
by fitting the SpotOn100 2-state (bound-free) kinetic model (0.05 µm2/s as maximum Dbound and 0.02 
µm2/s as minimum Dfree) to the distribution of translocations for individual molecules, obtained with 
TrackMate. For SRRF imaging, 100 frames were acquired for each cell. SRRF images were generated 
by running the NanoJ-SRRF ImageJ101 plugin on groups of 100 diffraction-limited images using the 
default settings.  
 
3.5. Flow cytometry 
Twenty-four hours after transfection with the corresponding constructs, cells were washed once 
with Ca2+- and Mg2+- free PBS and then detached with TrypLE Express dissociation reagent for 5 min 
at 37ºC. Complete DMEM medium was added to the cells to neutralize TrypLE, and cells were collected 
to a microcentrifuge tube. Cells were centrifuged at 300 g for 5 min at room temperature, the supernatant 
was discarded, and pellets were resuspended in PBS. Fluorescent levels were determined using a 488 
nm excitation laser and a 582/42 fluorescent filter. Flow cytometry was performed at Instituto Gulben-
kian de Ciência on a FACSCalibur cytometer using Cell Quest software (Beckton Dickinson, Franklin 
Lakes, NJ, USA). Ten thousand events per experimental group were acquired and results were analyzed 
using FlowJo software (Tree Star Inc., Ashland, OR, USA). 
  
3.6. Immunoblotting 
Cells were washed once with PBS 1X and then incubated with a lysis buffer (50 mM Tris-HCl, 150 
mM NaCl, 1% (v/v) NP-40 pH 7,5) supplemented with a protease inhibitor cocktail (Amresco, Fountain 
Parkway Solon, OH, USA). Cells were collected by scraping, transferred to microcentrifuge tubes, and 
incubated in ice for 10 min. To release intracellular proteins, cells were sonicated for 5 s using a Sonifier 
W - 450 D sonicator (Emerson, St. Louis, MO, USA). Proteins were collected after cell lysate centrifu-
gation at 10000 g for 10 min at 4ºC and quantified by means of the Bradford method. Briefly, proteins 
were incubated with Bradford reagent (ApploChem Panreac, Cinisello Balsamo, Milan, Italy) for 10 
min in the dark before measuring the absorbance at 595 nm. Protein concentrations were calculated by 
means of a standard curve of known bovine serum albumin (BSA) concentrations (0.125 to 2 µg/µL). 
For SDS-PAGE immunoblotting, 25 µg of total protein extracts were mixed with 4X loading buffer (4% 
(v/v) sodium dodecyl sulfate (SDS), 10% (v/v) 2- mercaptoethanol, 20% (v/v) glycerol, 0.004% (v/v) 
bromophenol blue, 0.125 mM Tris-HCl, at pH 6,8), boiled at 95ºC for 5 min to denature proteins, and 
incubated on ice for 5 min. Protein samples were separated by electrophoresis using a 10% (w/v) SDS-
polyacrylamide gel and run at 125 V for 1 h. Proteins were transferred to a nitrocellulose membrane at 
100 V for 1 h. Membranes were stained with 0.1% (w/v) Ponceau S to confirm sample quality and then 
washed with Milli Q water and Tris-HCl buffer saline (TBS) (150 mM NaCl, 50 mM Tris pH 7,4). 
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Membranes were subsequently blocked with 5% (w/v) non-fat dry milk in Tris-HCl buffer saline-Tween 
solution (TBS-T) (0.5% Tween-20) for 1 h at room temperature. After 3 washing steps with TBS-T, 
membranes were incubated with primary antibodies (diluted in 3% (w/v) BSA, 0.05% (v/v) sodium 
azide (NaAZ) in TBS-T) against GFAP (1:1000) and GAPDH (1:2000) overnight at 4ºC in a rotating 
wheel. To remove unbound antibody, membranes were rinsed 3 times with TBS-T for 10 min followed 
by an incubation with a secondary HRP-conjugated antibody (1:10000) in 5% (w/v) non-fat dry milk, 
for 2 h at room temperature with agitation. Membranes were rinsed 3 times for 10 min with TBS-T, 
incubated with chemiluminescent HRP substrate and imaged in a ChemiDoc XRS+ system (Bio-Rad, 
Hercules, CA, USA).  
 
3.7. Statistical analysis 
Statistical analysis and graphical representation of data were performed using Sigmaplot software 
(Systat Software, Inc., San Jose, CA, USA). Sample data are represented as mean ± standard deviation 
(SD) of at least 3 independent experiments. Statistical significance was evaluated by means of a one-
way ANOVA followed by a Tukey’s test. Results were considered significant when p < 0.05, but in 
some cases, we also specified lower significance thresholds (p<0.01; p<0.001). 
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4. Results 
 
Green fluorescent protein (GFP) and its spectral variants are versatile biological markers that have 
significantly changed our ability to study protein localization, dynamics, and interactions in living 
cells102,103. However, these fluorescent proteins also have several disadvantages, including their low 
photostability and brightness when compared to organic dyes, the potential formation of homo-oligo-
mers and limited choices in spectral wavelengths104,105. Due to these biophysical and photophysical prop-
erties, fluorescent proteins are often inadequate for super-resolution microscopy. An attractive alterna-
tive approach is the use of self-labeling protein tags, such as the HaloTag106, a hybrid approach that 
combines the genetic specificity of fluorescent proteins with the superior photophysics of organic dyes. 
The HaloTag is a genetically engineered derivative of a hydrolase that, in physiological conditions, 
efficiently forms a highly specific and irreversible covalent bond with a multitude of synthetic chloro-
alkane ligands, including a variety of spectrally distinct fluorescent tags, affinity tags, and attachments 
to solid supports. 
 
4.1. Mouse GFAP-HaloTag fused plasmid is successfully expressed in U251 cells 
 
We started by testing the effect of expressing a mGFAP-EGFP construct in U251 human glioblas-
toma cells and C6 rat glioma cells by transient transfection. This construct was able to incorporate into 
the endogenous IF network and form a normal filamentous pattern when expressed in U251 cells (Fig-
ure 4.1A), but not in C6 cells (Figure 4.1B), reflecting that the behavior of GFAP is not universal and 
depends on the cellular context.  
 
In order to study the architecture and behavior of GFAP at a nanoscopic level in living cells, we 
constructed a mouse-GFAP-HaloTag (mGFAP-HT) plasmid. This plasmid, as described in the Materials 
and Methods section, was generated by substitution of the EGFP tag from a host pEGFP-N3-mGFAP 
(mGFAP-EGFP) plasmid for a HaloTag using BamHI and NotI restriction sites and keeping the molec-
ular linker between GFAP and HaloTag. As seen in Figure 4.1C, our mGFAP-HT construct was also 
able to form a normal filamentous network similar to that of mGFAP-EGFP, when transiently expressed 
in U251 cells. Furthermore, the application of the SRRF algorithm to the widefield images of mGFAP-
HT was able to reconstruct these diffraction-limited low-resolution images into high-resolution images 
and provide higher resolution details about the architecture of GFAP fibrils (Figure 4.1D).	 					
 
 
 
 
 
 
 
 
 
Figure 4.1: Halo mouse GFAP is successfully ex-
pressed in U251 human glioblastoma cells. 
mGFAP-EGFP construct exhibited a normal GFAP 
filamentous network, when transiently expressed in 
U251 cells (A), but not in C6 cells (B). (C) U251 cells 
transfected with the mGFAP-HT construct and la-
beled with the JF549 Halo ligand (100 nM) also dis-
played a normal filamentous network characteristic 
of GFAP. (D) Widefield images of the mGFAP-HT 
construct were further analyzed with the NanoJ Su-
per-Resolution Radial Fluctuations (SRRF) algo-
rithm, which provided higher resolution details about 
the GFAP fibrils. Scale bars - 10 µm. 
U251 C6 
U251 U251 
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4.2. Alexander disease-causing mutation R236H is deleterious to the assembly and network for-
mation of mouse GFAP  
 
To understand the effect of AxD-causing mutations on the assembly properties of GFAP, a R236H 
AxD-mutant was generated by site-directed mutagenesis. Transient transfection of WT mGFAP into 
U251 cells resulted in its incorporation within the endogenous IF network and in the formation of fila-
ment networks (Figure 4.2A, left panel) in approximately 87% of the transfected cells (Figure 4.2B). 
A diffuse homogeneous pattern or an aggregation pattern was occasionally observed in 11% and 2% of 
the transfected cells, respectively (Figure 4.2B). In contrast, transient expression of the R236H AxD-
mutant disrupted the endogenous GFAP network, as the majority of the cells did not display an obvious 
filamentous structure (Figure 4.2A, right panel). Instead, GFAP either distributed homogeneously 
throughout the cytoplasm (45% of the cells) or formed cytoplasmatic inclusions (15% of the cells) (Fig-
ure 4.2B). 
 
 
 
 
 
 
 
 
We next analyzed the dynamics of the mGFAP-HT construct using single-molecule tracking, a 
powerful method to probe the mobility of molecules in living cells107. Images from living cells labeled 
with the fluorescent HaloTag ligand PA-JF549 were acquired to generate 2D single-molecule tracks of 
the movement of each GFAP molecule. GFAP molecules do not have all the same diffusion motion, and 
we can clearly distinguish between molecules that have limited dynamics (Figure 4.3A and 4.3B, cir-
cle), and molecules exhibiting rapid diffusion or directional motion (Figure 4.3A and 4.3B, arrow). To 
evaluate quantitatively the diffusive properties of GFAP we used the Trackmate ImageJ plugin to detect, 
localize and fit and track individual molecules. As observed in Figure 4.3C this plugin was able to 
detect with high accuracy the different GFAP molecules, in each frame. The individual tracks obtained 
were exported directly into the web-interface Spot-On and it was assumed that GFAP molecules could 
be distributed into 2 distinct subpopulations: a slow diffusion population and a rapid diffusion popula-
tion. The Spot-On model does not account for directional motion or confined diffusion but was sufficient 
to provide a good fit for diffusion jump distributions for single-cell data. 
Figure 4.2: Alexander disease-related R236H mutation causes filament disorganization of GFAP. U251 cells were tran-
siently transfected with either WT or mutant R236H GFAP, and 24 h later labeled with the JF646 Halo ligand (100 nM). (A) 
When expressed in this cell line, WT GFAP assembled into filaments (left panel), but mutant GFAP mostly formed a homoge-
neous pattern throughout the cytoplasm without any apparent filament structures (right panel). (B) Quantification of the various 
patterns observed for transfected U251 cells with WT GFAP (black bars) and mutant GFAP (white bars). Results are shown as 
mean ± SD of triplicates. * significant versus WT GFAP. ** p<0.01, *** p<0.001. Scale bar – 20 µm. 
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B) C) 
A) 
Figure 4.3: GFAP molecules display different diffusion behaviors. (A) Different types of diffusion motion of GFAP mole-
cules. arrow – fast-diffusing molecule; circle – slow-diffusing molecule. (B) Z-stack projection of the different diffusion mo-
tions of GFAP molecules. arrow – fast-diffusing molecule; circle – slow-diffusing molecules. (C) Detection of GFAP mole-
cules with the Trackmate ImageJ plugin. Scale bars – 5 µm. 
  
18 
Spot-On analysis of the R236H mutant demonstrated that this mutation has a strong effect on the 
dynamics of GFAP molecules, and results in a significant increase in the rate of diffusion when com-
pared to the WT (from ~ 0.13 µm2/s to ~0.21 µm2/s) (Figure 4.4A). However, the fraction of slow-
diffusing R236H GFAP molecules does not differ from WT (Figure 4.4B). To further characterize the 
dynamics of GFAP, cells were treated with either LIF (100 ng/ml) to activate endogenous GFAP ex-
pression, nocodazole (10 µM), an antineoplastic agent that interferes with the polymerization of micro-
tubules or latrunculin B (10 µM), a drug that disrupts actin filaments. Results revealed that the increase 
in GFAP expression by LIF had little effect on the diffusion of GFAP molecules (Figure 4.4C), but 
increased, slightly, the fraction of slow-diffusing molecules (Figure 4.4D). Conversely, destabilization 
of the actin and microtubules networks significantly decreased the diffusion of GFAP molecules (Figure 
4.4C) and increased the fraction of slow-moving molecules (Figure 4.4D), which emphasizes the im-
portance that actin filaments and microtubules have on the dynamics and maintenance of the GFAP 
network. 
 
Figure 4.4: AxD-related R236H mutation alters the diffusion properties of mGFAP. (A) Average diffusion coefficient 
(µm2/s) of rapid-diffusing molecules and (B) fraction (%) of slow-diffusing GFAP molecules calculated for individual cells by 
Spot-On for WT GFAP (20 cells) and R236H mutant (20 cells). (C) Average diffusion coefficient (µm2/s) of rapid-diffusing 
molecules and (D) fraction (%) of slow-diffusing GFAP molecules calculated for individual cells by Spot-On for WT GFAP 
untreated (20 cells) and treated with LIF (100 ng/ml, 20 cells), Nocodazole (10 µM, 20 cells) or Latrunculin B (10 µM, 20 
cells). Results are shown as mean ± SD. ns – non-significant; * significant versus WT GFAP. * p<0.05, *** p<0.001. 
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4.3. Generation of tagged human-GFAP constructs 
 
Previously, we generated a human-GFAP-EGFP (hGFAP-EGFP) fused construct by randomly in-
serting the coding region of EFGP into the coding region of hGFAP, following a technique described 
elsewhere108. Briefly, in the presence of a transposase protein, a 1902 bp transposon containing the cod-
ing region for EGFP and kanamycin resistance (Kanr) was inserted, randomly, into a pcDNA3.1/Ampi-
cillin (Ampr) resistant target plasmid containing the coding region for human GFAP. Successfully trans-
posed plasmids carried both Ampr and Kanr as selection markers (Figure 4.5A). The transposon inser-
tion was confirmed by PCR-based colony screening using primers specific for GFAP. Positive colonies 
were then digested with Srf1 to remove the Kanr region, and the resulting plasmids were transfected into 
U251 cells and tested for fluorescence by means of flow cytometry and fluorescence microscopy. 
 
Using the hGFAP-EGFP fused plasmid and the same cloning strategy described previously in Sec-
tion 3.2.1, we generated two new hGFAP constructs by substituting the EGFP tag of the hGFAP-EGFP 
plasmid for a Venus 1 (amino acids 1-157) or Venus 2 (amino acids 158-238), in order to create a 
Biomolecular Fluorescent Complementation (BiFC) system (Figure 4.5B). BiFC systems are an im-
portant tool to visualize and study protein-protein interactions in living cells. The BiFC is a two-plasmid 
system where the proteins of interest, in our case human GFAP, are fused to either the N-terminal half 
(V1) or the C-terminal half (V2) of the Venus fluorescent protein. These Venus fragments are not fluo-
rescent by themselves. However, if the proteins of interest interact, the Venus halves come together, 
reconstitute the native structure of the fluorophore and emit fluorescence (Figure 4.5C)109. Such system 
would allow us to identify or visualize hGFAP interactors in living cells or quantify the formation of 
hGFAP dimers during the process of fibrillization. 
 
When transfected into U251 cells, our hGFAP-BiFC system produced a fluorescent signal, as de-
tected by flow cytometry, indicating the constructs were successfully expressed (Figure 4.5D). How-
ever, the number of fluorescent cells was very low. Fluorescence microscopy results were consistent 
with flow cytometry results, as only a very low number of cells were fluorescent, and they showed low 
fluorescence that quickly photobleached. In contrast to our hGFAP-EGFP construct, which was able to 
form filamentous networks typical of GFAP in both U251 (Figure 4.5E, left upper panel) and C6 
(Figure 4.5E, left bottom panel), the BiFC system failed to form such networks, but instead formed 
aggregates with no apparent filamentous structure (Figure 4.5E, right upper panel). This was essen-
tially the same result our laboratory obtained when we previously tried to create a hGFAP BiFC system 
adding the BiFC tags to the N- or C-termini of the hGFAP protein. 
 
We also used our hGFAP-EGFP construct as a host vector for the generation of a hGFAP-HaloTag 
construct, in an attempt to reproduce our results with mGFAP (Figure 4.5B). Similar to the BiFC sys-
tem, this construct did not form any filamentous structure in living cells labeled with the JF646 ligand 
(100 nM) but instead formed small aggregates dispersed throughout the cytoplasm of the cells (Figure 
4.5E, right bottom panel). These results were the same when cells were labeled with the JF549 ligand 
(100 nM) (Data not shown). 
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Figure 4.5: Construction of tagged human GFAP plasmids. (A) Transposon strategy to generate human GFAP-EGFP fused 
constructs. (B) Human GFAP constructs were obtained by substitution of the EGFP tag of the pcDNA3.1-EGFP-hGFAP plas-
mid by Venus 1 (amino acids 1-157), Venus 2 (amino acids 158-238) or full-length HaloTag. (C) The schematic principle of 
the BiFC system. (D) Flow cytometry charts of untransfected U251 cells (negative control, left panel) and cells transfected 
with the GFAP BiFC system (right panel). (E) Fluorescent microscopy analysis revealed that our hGFAP-EGFP construct is 
able to form characteristic GFAP filaments when transiently expressed in U251 cells (left upper panel) and in C6 cells (left 
bottom panel). In contrast, U251 cells transiently transfected with the hGFAP BiFC system (right upper panel) or with the 
hGFAP-HT construct and labeled with JF646 ligand (100 nM) (right bottom panel) do not display any apparent filaments, but 
instead, GFAP forms small aggregates throughout the cytoplasm of the cells. Scale bar – 20 µm. 
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4.4. Alexander disease-related R239C mutation induces human GFAP aggregation 
 
Next, we tested the effect of expressing wild-type GFAP and the R239C mutant, generated by site-
directed mutagenesis, in U251 cells. Western-blot analysis confirmed the expression of both constructs 
in U251 cells and revealed that GFAP levels were similar between cells transfected with WT and mutant 
GFAP (Figure 4.6A). While cells transfected with WT GFAP exhibited a typical filamentous network 
(Figure 4.6B, left panel), cells transfected with the Alexander-disease R239C mutant showed GFAP 
inclusions dispersed throughout the cytoplasm (Figure 4.6B, right panel). The pattern of aggregation 
and the size of the aggregates displayed by mutant GFAP varied significantly between cells, with some 
cells exhibiting less numerous but larger aggregates and others exhibiting a large number of small ag-
gregates. Quantification of microscopy data revealed that about 90% of the cells transfected with WT 
GFAP contained filaments, while this percentage dropped to about 40% for cells transfected with the 
mutant form of GFAP. On the other hand, while only 3% of the cells transfected with WT GFAP showed 
an aggregation pattern, this percentage significantly increased to 48% for cells transfected with the 
R239C mutant (Figure 4.6C). 
 
 
Figure 4.6: Transient expression of mutant R239C GFAP leads to aggregate formation in U251 cells. (A) U251 cells were 
transfected with the indicated GFAP constructs and total protein extractions were analysed by immunoblotting using an anti-
GFAP antibody that recognizes both endogenous and exogenous GFAP. (B) Filamentous and aggregate patterns formed by 
WT GFAP (left panel) and R239C mutant GFAP (right panel), respectively. (C) Distribution of patterns after transfection of 
WT (black bars) and mutant (white bars) constructs into U251 cells. * significant versus WT GFAP.  ***p<0.001. Scale bar – 
20 µm.  
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Although there is still no treatment for AxD, several drugs and compounds targeting GFAP expres-
sion and accumulation have been screened in multiple in vitro cell assays. Given the reported beneficial 
effects of curcumin in a cellular model of Alexander disease, we sought to test the neuroprotective effect 
of two synthetic and improved curcumin derivatives, J147 and CNB-001, on GFAP accumulation. To 
this end, cells transfected with the R239C mutant GFAP were treated with 100 nM, 1 µM or 10 µM of 
each drug. As shown in Figure 4.7, only cells grown in the presence of 10 µM of CNB-001 showed a 
significant increase in filament formation and a corresponding decrease in GFAP aggregation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: CNB-001 has a beneficial neuroprotective effect on GFAP filament organization and accumulation. Quanti-
fication of U251 cells transfected with the GFAP R239C mutant that displayed a normal filamentous network (black bars) or 
aggregates (white bars) after treatment with increasing concentrations (0.1-10 µM) of the neuroprotective compounds J147 or 
CNB-001. Results are shown as mean ±SD of triplicates. All groups were statistically significant versus WT (p<0.001). * 
significant versus R239C mutant GFAP. * p<0.05, ***p<0.001. 
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5. Discussion 
 
The cytoskeleton is a complex network of protein filaments and motor proteins that provides the 
structural framework of cells and helps them divide, move and maintain their shape. This dynamic and 
adaptive structure is composed of three main types of filaments, distinguishable by their size: actin fil-
aments or microfilaments, microtubules and a group of polymers collectively known as intermediate 
filaments31,35. At present, IFs are the least characterized filaments of the cytoskeleton, and our current 
knowledge at the level of mature filaments is still far from complete, as the exact three-dimensional 
structure of the filaments, as well as the dynamic processes of filament maturation, are yet to be fully 
understood. This shortage of knowledge regarding the organization and dynamics of IFs, and in partic-
ular of GFAP, is attributed, at least in part, to the lack of chimeric versions of GFAP, making it difficult 
to visualize and study this protein in vivo. In fact, the attachment of protein tags directly to the N- or C- 
termini of GFAP cause a disruption of the filament network and increase the tendency of the protein to 
aggregate84. In this sense, our study aimed to create new molecular tools to study the behavior of GFAP 
in living cells. 
 
In this work, we started by developing a new tool to study the behavior of mouse GFAP. EGFP-
tagged mouse GFAP has been previously used to study GFAP function and dynamics110. This was the 
first time GFAP was successfully tagged, and it was thanks to the introduction of a flexible molecular 
linker between GFAP and EGFP, which enabled correct folding of GFAP and facilitated the integration 
of GFAP within the endogenous intermediate filament network of U251 glioma cells. However, bio-
physical and photophysical limitations of the green fluorescent proteins and its variants make them un-
usable in some super-resolution microscopy and in long live-cell experiments104,105. In order to study the 
architecture and behavior of GFAP at a nanoscopic level in living cells, we constructed a mouse-GFAP-
HaloTag (mGFAP-HT) fused plasmid, keeping the molecular linker between GFAP and HaloTag. The 
HaloTag is an attractive alternative to fluorescent tags approach because it combines the genetic speci-
ficity of fluorescent proteins with the superior photophysics of organic dyes106.  
 
While studies using fluorescently tagged mouse GFAP have been previously reported, no studies 
have been published involving fluorescently tagged human GFAP. In this study, we also successfully 
developed the first tagged version of human GFAP, by inserting an EGFP tag inside the coding region 
of GFAP (hGFAP-EGFP). This protein tag was inserted by a randomized approach between amino acids 
181 and 183 in the segment 1B of the conserved rod-domain of GFAP. Interestingly, this region contains 
very few mutations related to Alexander disease61. Our hGFAP-EGFP construct, like the mGFAP-HT 
construct, was able to successfully form a filamentous network when expressed in U251 cells. GFAP 
behavior is not universal and the ability of this protein to form filaments depends strongly on the cellular 
environment. Our results demonstrate that our hGFAP construct is more versatile that the mGFAP, as it 
was able to produce filaments in both human and rat cells, opposingly to the mGFAP construct, which 
only produced filaments when transfected into human cells. We also used our hGFAP-EGFP construct 
as a host vector for the generation of a hGFAP-BiFC system and a hGFAP-HT plasmid, but without 
success. Both constructs did not form any filamentous structures in living cells but instead formed small 
aggregates in the cytoplasm of the cells. We speculate that the introduction of these tags disrupts the 
normal folding of GFAP and increases the tendency of the protein to aggregate. We are currently con-
sidering the possibility to add linkers between the tags and the surrounding GFAP sequence. 
 
Previous studies reported that Alexander disease mutations disturb in vitro filament assembly and 
network formation by GFAP80,110. The evidence that the mouse R236 or the human R239 mutations in 
GFAP interfere with filament assembly is further supported by the fact that a mutation homologous to 
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this, R249Q, has been found in the type-V intermediate filament lamin A/C111. This mutation affects the 
structure of nuclear lamin, and patients with this mutation develop autosomal dominant Emery-Dreifuss 
muscular dystrophy. Furthermore, structures that resemble Rosenthal fibers have been observed in my-
opathies caused by dominant mutations in the intermediate filament desmin112. Our results confirm these 
observations, as the majority of cells expressing mouse R236H or human R239C mutant GFAP do not 
display a typical filamentous network. While the human R239C mutant is mostly organized in inclu-
sions, mouse R236H mutant GFAP formed a homogeneous pattern without apparent filament structures. 
This observation contrasts a previous study110, where mutant R236H mouse GFAP-EGFP tagged pre-
dominantly formed aggregates. This difference could be due to the difference of tags, as the HaloTag 
might be inhibiting the formation of aggregates. Additionally, mutant GFAP does not behave the same 
in all cells80, as in some cells mutant GFAP was able to incorporate into the endogenous GFAP network 
and form filamentous structures. Murine models of AxD87,113 showed that overexpression (approxi-
mately 3-fold increase) of mutated GFAP is an important factor in its aggregation. However, we ob-
served aggregate formation in our hGFAP-EGFP model without an obvious increase in GFAP levels. 
Accumulation of GFAP without an overall increase in its levels may represent an early stage of disease 
and suggests that mutations in GFAP are sufficient to induce aggregation.  
 
Although some efforts have been made toward the discovery of drugs and compounds against AxD, 
the truth is that this disease remains uncurable. Recent findings, however, demonstrated a beneficial 
effect of the spice curcumin, in reducing GFAP accumulation114. To improve the effectiveness of cur-
cumin, two synthetic derivatives of curcumin, J147115 and CNB-001116 were previously synthesized by 
Dr. Schubert’s laboratory (The Salk Institute, CA, USA). Of the two, J147 is the best-studied curcumin 
derivative and has been proven effective in various rodent models of neurodegenerative disease and 
memory enhancement117,118. CNB-001 has been proven to have a neuroprotective activity in cell culture 
assays116. When we tested the neuroprotective activities of these two molecules in a cellular model of 
AxD, we observed that only CNB-001, and at a concentration of 10 µM, showed a slight but significant 
increase in filament formation and a decrease in GFAP accumulation. Our data support the hypothesis 
that CNB-001 does have a beneficial role in reducing GFAP accumulation and that CNB-001 is more 
efficient than J147, at least in our cellular model of AxD. As curcumin proved to be best efficient in a 
concentration range between 15-40 µM114, further studies will need to be done using higher concentra-
tions of J147 and CNB-001, to find out what is the most beneficial concentration of each compound. A 
recent report119 showed that the neuroprotective properties of J147 came from its binding and partial 
inhibition of the activity of ATP synthase, which in turn causes an increase in intracellular calcium and 
activates the AMPK/mTOR pathway, which is involved in cell growth, proliferation, and survival. The 
cellular targets of CNB-001 are not known, but it is hypothesized that this drug might share some posi-
tive pharmacological traits with curcumin, such as its ability to stimulate innate neuroprotective path-
ways via the activation of phase 2 enzymes116. 
 
There is increasing evidence demonstrating that IFs are highly dynamic structures that are con-
stantly rearranging in response to various stimuli. However, their dynamic properties remain unclear. In 
this study, we used single-molecule techniques to probe the motility of individual GFAP molecules in 
living cells. By labeling our mGFAP-HT construct with the fluorescent HaloTag ligand PA-JF549, we 
showed that the R236H AxD-related mutation has a strong effect on the dynamics of GFAP molecules. 
In fact, the mutation appears to increase the rate of diffusion of GFAP, which at first sight seems to 
contradict a previously proposed model58,67 in which the effect of the mutations is to slow down the rate 
of polymer formation. We find two possible interpretations for our results. First, AxD-inducing muta-
tions could increase the rate of filamentation that pushes the boundaries of the fibril dynamics to a 
breaking point, as the rate of removal of old monomers from the fiber does not occur at the same speed 
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as the entrance of new monomers in the fiber. This could create a “traffic jam” in the fiber, and favor 
the production of aggregates, collapse of filaments or aberrant interactions with close filaments or other 
proteins. Alternatively, our data showing faster diffusion could be interpreted as poorer formation of 
fibers, which could increase the number of free diffusing GFAP monomers. While it is clear that AxD 
mutations disrupt fiber formation, further analysis will be needed to ascertain the exact mechanism. 
 
IFs are in constant communication with the other elements of the cytoskeleton, and very often their 
dynamics requires the participation of microtubules and actin filaments. Consistent with recent find-
ings14, depolymerization of actin microfilaments or microtubules resulted in a significant reduction of 
the diffusion of GFAP and an increase in the percentage of immobile/slow-diffusing molecules. Our 
findings demonstrate that actin depolymerization has a stronger effect in decreasing GFAP diffusion 
than microtubule depolymerization. This result, however, seems to disagree with the finding that actin 
depolymerization does not block the emergence of fast-moving IFs along microtubules14, so we would 
expect that the diffusion of GFAP molecules would be slower when we depolymerize microtubules. 
This discrepancy may result from a partial depolymerization of microtubules, as we did not incubate the 
cells at 4ºC before adding Nocodazole, as some authors suggest120. 
 
Our dynamics data result from fitting the different trajectories to a 2-state kinetic model, where we 
assume the existence of two populations with different diffusion properties: one population with a very 
slow diffusion, that might represent GFAP molecules inside fibers, and another population of molecules 
not in fibers with a faster diffusion. This is, however, a simplification of the actual number of different 
GFAP populations that might exist in a cell. Some suggest that IFs can be found in at least three different 
forms: mature filaments, short filaments of different sizes and non-filamentous particles120. Our data fit 
very well to a 2-state model and this might be due to the fact that, with our imaging settings, we were 
unable to continuously track GFAP particles or small structures as they move too fast and quickly go 
out-of-focus. A way to image this fast-diffusion population is by increasing the laser power and faster 
imaging (reduce the exposure time); this will also increase the rate of PA-JF549 photobleaching and 
allow for a higher density of molecules to be tracked at the expense of shorter trajectory lengths. Another 
way to get more and longer tracks is by introducing three-dimensional imaging (Z-stacks), which would 
allow the tracking of molecules that quickly go out-of-focus. However, doing Z-stack acquisitions may 
decrease temporal resolution of particles that are always in the same plane. An alternative to collecting 
Z-stacks is encoding Z position in the shape of the image of a molecule by phase modulation, which can 
localize a molecule through ~5 µm at the expense of lower signal: noise and lower density during ac-
quisition. We are currently studying these possibilities in order to make a more complete and accurate 
description of GFAP behavior. 
 
In sum, in this thesis, we developed two novel and versatile systems for the study of GFAP behavior 
in living cells, and that can easily be applied for the study of other IFs. The development of new and 
more versatile molecular tools, however, continues to be indispensable to better understand the function, 
structure, and dynamics of GFAP in living cells, and to understand the mechanisms by which GFAP 
mutations cause Alexander disease and lead to astrocyte dysfunction. 
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6. Main Conclusions 
 
In the present study, we successfully developed two novel systems to study the behavior of GFAP 
in normal and AxD-related conditions, a new and more versatile tool for the study of mouse GFAP by 
super-resolution microscopy or other advanced methods and the first tagged version of human GFAP. 
These tools allowed us to conclude that: 
 
1. The ability of tagged GFAP to form filaments depends strongly on the cellular environment and 
the tags themselves; 
 
2. Mouse R236H and human R239C AxD-causing mutations are deleterious to the assembly and 
network formation and alter the dynamic properties of the intermediate filament GFAP; and 
 
3. GFAP dynamics and network maintenance are tightly associated to the dynamics of the other 
cytoskeleton proteins. 
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